Response to vaccination against tetanus in chronic haemodialysed patients.
We studied the response to vaccination against tetanus and the changes in the antibody titers 6 months after this vaccination in 66 haemodialysed patients with chronic renal failure. We also investigated the factors that may affect the quality of this immune response. After the booster injection 96.5% of patients had antitetanus antibody titres considered to be protective (0.06 HU/ml). However, the titre of these antibodies rapidly declined and after 6 months, only 62% of the haemodialysed patients had a titre greater than 0.06 HU/ml. Among the different factors considered, only age significantly impaired or reduced the immune response. In addition, the acquisition of protection against tetanus was independent of the response to vaccination against hepatitis B in the same subjects. This study showed the efficacy and safety of vaccination against tetanus in hemodialysed patients, though the antibody titres should be assayed several months after vaccination to confirm the persistence of immunization.
Guerin
A
A
F.H. Manhès, Hospital Center Fleury Mérogis, France.
Buisson
Y
Y
Nutini
M T
MT
Saliou
P
P
London
G
G
Marchais
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D003017:Clostridium tetani / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D017325:Hepatitis B Vaccines; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis; D013745:Tetanus Toxoid / Q000009:adverse effects / Q000494:pharmacology*; D014761:Viral Hepatitis Vaccines / Q000494:pharmacology
D000907:Antibodies, Bacterial; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D013745:Tetanus Toxoid; D014761:Viral Hepatitis Vaccines